Contrave, A New Weight Loss Pill Combines Anti-Addiction Medication And An Antidepressant

Contrave, A New Weight Loss Pill Combines Anti-Addiction Medication And An Antidepressant.
An crackerjack notice panel recommended on Tuesday that Contrave, a imaginative weight-loss pill that combines an antidepressant with an anti-addiction medication, be approved by the US Food and Drug Administration. The 13-7 come out in favor of Contrave came amid agency concerns that the remedy might raise blood pressure in some patients and increase the risk of heart attacks and strokes to each some users, according to the Associated Press breastpenis.club. But panelists voted 11-8 earlier in the date that those potential health risks could be studied after Contrave was approved.

The FDA does not have to follow the advice of its advisory committees, but it typically does. The force is expected to make a decision on Contrave by Jan 31, 2011, the wire mending reported. contrave is manufactured by orexigen therapeutics inc. In October, the FDA voted against approving two other weight-loss drugs, Arena Pharmaceuticals' lorcaserin and Vivus' Qnexa, because of safeness concerns, according to the AP pasang. Last July, a swatting funded by Orexigen and published in The Lancet found that Contrave helped users pour forth pounds when taken along with a tonic diet and exercise.

People who took the drug for more than a year lost an average of 5 percent or more of body weight, depending on the amount used, the team said. However, the regimen did come with side effects, and about half of investigate participants dropped out before completing a year of treatment. Contrave is combination of two prominent drugs, naltrexone (Revia, used to fight addictions) and the antidepressant bupropion (known by a include of names, including Wellbutrin).

The drug appears to boost weight loss by changing the workings of the body's key nervous system, the researchers said. The study enrolled men (15 percent) and women (85 percent) from around the country, ranging in duration from 18 to 65. They were all either paunchy or overweightm, with high blood fat levels or high blood pressure.

The participants were told to break bread less and exercise, and they were randomly assigned to take a twice-daily placebo or a array of the two drugs at one of two levels. After 56 weeks, only about half (870) of the more than 1700 participants initially enrolled remained in the study. Almost half (48 percent) of those who took the highest dispense of naltrexone bygone 5 percent of their weight or more, while only 16 percent of those who took placebos did.

However, about 30 percent of those taking Contrave efficient nausea, the study authors say, and other attitude effects included headache, constipation, dizziness, vomiting and dry mouth. Still, Contrave may give males and females struggling to lose weight a new option, the researchers contended.

The Lancet findings repercussion those of studies into other diet drugs such as Meridia, Xenical and Alli, said Lona Sandon, an aide-de-camp professor of clinical nutrition at the University of Texas Southwestern Medical Center in Dallas and spokeswoman for the American Dietetic Association. "When these are combined with a modestly reduced calorie diet, sensible amounts of arrange loss are achieved. One striking loathing to note is the study drop-out rate of 50 percent. This may have been due to side effects of medications, the happening that it is hard to stick to dietary changes for 56 weeks, or the fact that slow and only modest cross loss did not meet participant expectations".

Cynthia Sass, a New York City-based nutritionist and author, added that drugs old to treat addiction also appear to help with weight control, supporting "the inkling that food can be addictive for many people". An accompanying Lancet editorial noted that one have is that blood pressure did not drop as much as expected in the higher weight-loss group ceria sek kecelakaan bersama mmah kandungku. "More data are needed to get a better overall assessment of cardiovascular jeopardy of this otherwise promising combination therapy for obesity," wrote Professor Arne Astrup, a nutrition experienced at the University of Copenhagen, Denmark.